After a heart attack in rats, a diabetes drug called dapagliflozin seems to calm down the heart’s inflammation by reducing harmful immune cells and chemicals, while boosting a helpful one that soothes the damage.

6

Pro

0

Against

Evidence from Studies

Supporting (1)

6

Community contributions welcome

6

Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition.

Cohort Study

Animal

2025 Dec 15

The study found that a drug called dapagliflozin reduced harmful inflammation and boosted helpful inflammation in rat hearts after a heart attack, exactly as the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition.

Score: 6

DOI: 10.1016/j.lfs.2025.124083

Similar Assertions

In rats that had a heart attack, a drug called dapagliflozin helped them live longer and made their hearts pump better, according to ultrasound scans.

6

0

78%

In mice with heart damage from interrupted blood flow, a diabetes drug called dapagliflozin helps calm down inflammation in tiny blood vessels and stops heart cells from dying too soon.

8

0

77%